Other Special Model-based In Vivo Screening Service
Tailored In Vivo Screening Solutions for Advanced Research
In vivo screening in animal models is a method of screening small molecules, genes, or biomarkers for drugs in living animals. This method effectively evaluates the physiological activity of a drug, specific gene, or biomarker. As a professional company dedicated to glycobiology research, CD BioGlyco has mastered industry-leading genetics and other biotechnologies, has developed a variety of Glycobiology Disease Models, and has won a large number of accolades in the field of In Vivo Glycobiology Disease Model Screening. Here, we provide professional and reliable special model-based in vivo screening services to our clients.
- Animal model construction
We select animal models that are closest to human physiological characteristics according to our client's research objectives. At the same time, we use Gene Editing Technologies such as CRISPR/Cas9 to perform gene knockout (KO), knock-in (KI), point editing (PE), or single-base editing (BE) on the animal models to mimic specific glycobiology diseases. - In vivo screening for genes
We provide simple and effective screening methods to screen genes in vivo in models. Since the complete gene sequence provides information about the organization and transcriptional sequence of all genes in the genome, double-stranded RNAs (dsRNAs) are designed to screen target genes efficiently and specifically.
dsRNA-mediated gene silencing is an effective technique for gene screening. We inject dsRNAs directly into embryos or animals that have produced RNA interference (RNAi)-inducible phenotypes. dsRNAs are genomically encoded and transcribed into individual transcripts that generate short interfering RNAs (siRNAs) from transgenic constructs.
To identify different glycosylation genes, we combine a large-scale screen of glycosylation genes using RNAi libraries. The functional clusters of genes screened include functions such as glycosylation response, transcription, and RNA regulation.
Here, the specific animal models we offer our clients for in vivo screening of glycobiology diseases include but are not limited to, the following.
Humanized Mice Model
Humanized mice are models in which human cells are xenografted and engineered to express human gene products. CD BioGlyco utilizes gene editing technology to knock in functional glyco-genes into mice to provide reliable humanized mice model-based in vivo screening service.
Alligator Model
Alligator has a powerful immune system that is highly inhibitory to most drug-resistant bacteria as well as viruses, including human immunodeficiency virus. CD BioGlyco utilizes the alligator model to provide clients with glycobiology disease screening services associated with drug-resistant bacteria and viruses.
Sea Anemone Model
Sea anemone is a powerful developmental model in which many techniques for manipulating gene expression can be used to good effect. CD BioGlyco utilizes a variety of transgenic technologies to customize sea anemone models for glycobiology diseases, providing a professional sea anemone model-based in vivo screening service.
Hydra Model
Hydra appears to have a complete DNA repair pathway and its unique tissue dynamics, continuous pattern formation make it a widely used disease model. CD BioGlyco offers a unique hydra model-based in vivo screening service based on its superior genetics expertise.
Leech Model
Leech can be easily propagated in a laboratory setting, which helps to obtain sufficient starting material for standard molecular and cellular analyses. CD BioGlyco has a team of researchers who specialize in the development of glycobiology disease models to provide a high-quality leech model-based in vivo screening service.
Marine Worm Model
The marine worm has a robust chemosensory neuron system with over 1500 G protein-coupled receptors (GPCRs) on its cell membrane, making it a highly sensitive model for disease diagnosis. CD BioGlyco has conducted in-depth research on the physiological activities of the marine worm chemosensory neuron system and has developed the marine worm model for in vivo screening of glycobiology diseases.
Publication Data
Technology: Caenorhabditis elegans models
Journal: Molecular Neurodegeneration
IF: 15.1
Published: 2016
Results: The authors constructed a Caenorhabditis elegans model and successfully analyzed protein aggregation within it. The authors experimentally demonstrated the progression of protein aggregation within a few days of each nematode within an individual, i.e., a mutated human superoxide dismutase 1-yellow fluorescent protein (SOD1-YFP) fusion protein in the body wall muscle. In addition, the authors succeeded in pinpointing the expression of biomolecules within nematode tissues and monitored the evolution of individual aggregates at the subcellular level for several days.
Applications
- Animal model-based in vivo screening services can be used to help researchers delve deeper into the mechanisms of disease and advance the science of medicine.
- Animal model-based in vivo screening services can be used to research the function of genes or their encoded proteins in organisms and to elucidate their roles in cellular processes.
- In vivo screening services based on animal models can be used to simulate human diseases to research the pathogenic mechanisms, developmental processes, related gene regulation processes, disease treatment methods, etc.
Advantages
- We provide our clients with accurate project processes and timelines and have an efficient and strictly quality-controlled production line.
- We conduct in-house research and development to promote the creation of novel animal models, which not only contribute to scientific research but also provide important support for drug development.
- We combine advanced technologies from multiple disciplines to provide customized animal models to our clients.
CD BioGlyco has the world's leading gene editing technology and genetic tools and has accumulated rich experience in the field of glycobiology disease model development for many years. With our mature technology and well-established process, we provide animal models of glycobiology diseases to meet different experimental needs. Please feel free to contact us if you have any questions about the glycobiology disease model.
Reference
- Cornaglia, Matteo; et al. Automated longitudinal monitoring of in vivo protein aggregation in neurodegenerative disease C. elegans models. Molecular Neurodegeneration. 2016, 11: 17.
